CLASS II Drug recall · Reported 30 Mar 2022 · FDA Enforcement Report

NAD+ Nicotinamide Adenine Dinucleotide recalled

Olympia Compounding Pharmacy is recalling NAD+ Nicotinamide Adenine Dinucleotide, Lyophilized powder for reconstitution, Multi-Dose, distributed nationwide in the US. The recall was initiated on 8 Mar 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot: D24005 Exp. 4/5/22; C41008 Exp. 3/8/22
Quantity recalled2634 vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0719-2022
FDA event ID
89717
Recalling firm
Olympia Compounding Pharmacy, Orlando, FL
Classification
Class II
Status
Terminated
Recall initiated
8 Mar 2022
FDA classified
29 Mar 2022
Reported
30 Mar 2022
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Sterility

Timeline

8 Mar 2022Recall initiated by company
29 Mar 2022Classified by FDA+21 days
30 Mar 2022Published in enforcement report+1 day

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Product found to be Sub Potent or Exceeded reconstitution time

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

NAD+ Nicotinamide Adenine Dinucleotide, Lyophilized powder for reconstitution, Multi-Dose 500 mg per vial, Each ML contains: 0.288% Sodium Phosphate Monobasic USP, 0.42% Sodium Phosphate Dibasic USP, 5% Mannitol USP, Sterile Water for Injection USP, Rx Only, Olympia Pharmaceuticals 6700 Conroy Rd., Ste. 155, Orlando, FL 32835 NDC: 73198-0083-00

Where it was distributed

Nationwide in the USA including Puerto Rico.

Nationwide Puerto Rico

Questions about this recall

Is NAD+ Nicotinamide Adenine Dinucleotide, Lyophilized powder for reconstitution, Multi-Dose recalled?

Yes. Olympia Compounding Pharmacy recalled NAD+ Nicotinamide Adenine Dinucleotide, Lyophilized powder for reconstitution, Multi-Dose on 8 Mar 2022. The recall is Class II and its status is Terminated. Recall number D-0719-2022.

Why was it recalled?

Product found to be Sub Potent or Exceeded reconstitution time

Which lots are affected?

Lot: D24005 Exp. 4/5/22; C41008 Exp. 3/8/22

Where was it sold?

Nationwide in the USA including Puerto Rico.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Olympia Compounding Pharmacy

All 94